Trial Summary
What is the purpose of this trial?This study aims to assess the clinical significance of cleavage stage (Day 3) assisted hatching compared to assisted hatching at the blastocyst stage (Day 5,6,7) of embryo development at the time of trophectoderm (TE) biopsy for patients undergoing in vitro fertilization (IVF) and preimplantation genetic testing for aneuploidy (PGT-A) for treatment of their infertility.
Eligibility Criteria
This trial is for individuals undergoing IVF with PGT-A due to infertility. It's comparing the timing of a technique called assisted hatching, either on Day 3 at cleavage stage or later on Days 5-7 at blastocyst stage before TE biopsy.Inclusion Criteria
My fertility tests show normal ovarian function and my BMI is under 38.
Exclusion Criteria
My partner has low sperm count or we are using donor sperm.
I have undergone surgery to collect sperm.
I have a fallopian tube condition and no surgery planned before embryo transfer.
My uterus lining is too thin or I have persistent fluid in my uterus.
I need detailed genetic testing for my embryo beyond standard screening.
Treatment Details
The study tests whether laser-assisted hatching should be done earlier (Day 3) or later (Days 5-7) in embryo development to improve IVF success rates. Participants will have one of these two procedures randomly.
2Treatment groups
Experimental Treatment
Group I: Cleavage Stage Assisted Hatching (AH)Experimental Treatment1 Intervention
Current standard of care. Day 3 or cleavage stage embryos will have the zona pellucida hatched with a laser.
Group II: Blastocyst Stage Assisted Hatching (AH)Experimental Treatment1 Intervention
Blastocyst stage embryos on day 5,6 or 7 will have the zona pellucida hatched with a laser.
Find a clinic near you
Research locations nearbySelect from list below to view details:
Reproductive Medicine Associates of New JerseyMarlton, NJ
Loading ...
Who is running the clinical trial?
Reproductive Medicine Associates of New JerseyLead Sponsor